NCT07220343Recruiting
Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer
Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 9 Sept 2025
- Start date
- 29 Jan 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Stanford University
- Diseases
- Childhood cancers
- NCT number
- NCT07220343
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 29 Jan 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Significant physical or mental disability that prevents completion of study activities
- Lack of proficiency in English or Spanish
Who the study is looking for
- 10-25 years old
- Recent cancer diagnosis (\>2 and \<18 months since diagnosis)
- Willing to carry smartphone on their person for duration of study participation
- Willing to wear smartwatch for duration of study participation
Age in the registry: 10 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.